Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase EARLY_PHASE1 × Brain Neoplasms × Azacitidine × Clear all

Phase

Phase EARLY_PHASE1 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Myelodysplastic Syndromes 2 Leukemia, Neutrophilic, Chronic 1 Leukemia, Myelomonocytic, Chronic 1 Leukemia, Myeloid, Acute 1 Ependymoma 1 Brain Neoplasms 1

Interventions

Magnetic Resonance Spectroscopy 6 Biopsy 3 Bevacizumab 3 posaconazole 2 fluciclovine F-18 2 Topotecan 2 Temozolomide 2 Specimen Handling 2 Radiosurgery 2 Pemetrexed 2 Nivolumab 2 Methotrexate 2 Ketoconazole 2 Fluorodeoxyglucose F18 2 ribociclib 1 relatlimab 1 mycophenolic adenine dinucleotide 1 montelukast 1 gancotamab 1 fluoromisonidazole 1 fluorodopa F 18 1 fludarabine phosphate 1 etoposide phosphate 1 eribulin 1 dexamethasone acetate 1 dexamethasone 21-phosphate 1 clevudine 1 ceritinib 1 brivaracetam 1 auricularum 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02940483 2018-11-30

5-AZA

The University of Texas Health Science Center, Houston

Phase EARLY_PHASE1 Completed

Brain Neoplasms, Ependymoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡